Chargement en cours...
The role of carfilzomib in relapsed/refractory multiple myeloma
Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and a...
Enregistré dans:
| Publié dans: | Ther Adv Hematol |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8191071/ https://ncbi.nlm.nih.gov/pubmed/34163580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20406207211019612 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|